<DOC>
	<DOCNO>NCT01485588</DOCNO>
	<brief_summary>Phase 1 : The purpose study evaluate safety tolerability single ascend dos hI-con1™ subject Age-Related Macular Degeneration . Phase 2 : The purpose study evaluate safety 3 injection hI-con1™ 2 different dose level .</brief_summary>
	<brief_title>Safety Tolerability Study Age-Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Ocular Active choroidal neovascularization ( CNV ) associate agerelated macular degeneration , evidence fluorescein angiography OCT , follow lesion characteristic : Subretinal hemorrhage present &lt; 50 % total lesion size During Phase 1 , 4th , 5th , 6th subject enrol cohort must total lesion area &lt; 6 DA ( total area detachment ) ( 15.24 mm2 ) , least 50 % must actively leak , 30 % classic angiography determine reading center , 3 prior injection therapy treatment CNV . For Phase 2 , total lesion area &lt; 6 DA ( total area detachment ) ( 15.24 mm2 ) , least 50 % must actively leak , 30 % classic angiography determine read center 3 prior injection therapy treatment CNV . BCVA Phase 1 : 20/ 80 count finger study eye ; visual acuity fellow eye must better study eye BCVA Phase 2 : 20/40 20/320 study eye ; visual acuity fellow eye must better study eye Only one eye subject treat study . If eye eligible , study eye eye bad visual acuity . If visual acuity eye , eye active CNV select study eye Clear ocular medium adequate pupillary dilation study eye permit fundus photography screen Intraocular pressure 21 mm Hg le study eye . General Inclusion Criteria Subjects either gender , &gt; 50 year age Subjects inform , willing able comply , investigational nature study able provide write informed consent Ability return study visit Females must nonchild bear potential ( surgically sterilize least 2 year postmenopausal ) childbearing potential , subject must negative serum pregnancy test within 14 day prior first injection agree use 2 form effective contraception trial least 60 day follow last study injection . Ocular Any retinal vascular disease retinal degeneration AMD study eye Serous pigment epithelial detachment without presence choroidal neovascularization study eye Pigment epithelial tear rip study eye Previous posterior vitrectomy retinal surgery study eye Any periocular infection past 4 week study eye During duration study , subject concomitant therapy antiVEGF agent , e.g. , Lucentis® , Avastin® , Macugen® study eye ( unless identify rescue therapy give accord protocol guideline ) Concomitant therapy use within 30 day Baseline ( Day 1 ) systemic ( e.g . intravenous , oral , intramuscular , rectal ) corticosteroid dose &gt; 10 mg/ day prednisone prednisone equivalent , use intravitreous periocular steroid within 90 day Baseline ( Day 1 ) study eye Any current prior use extendedrelease steroid implant ( e.g. , Retisert® , Posurdex® , Medidur® ) study eye Significant medium opacity , include cataract , study eye might interfere visual acuity , assessment toxicity , fundus photography . Cataract surgery study eye within three month screen Trabeculectomy outflowdevice glaucoma surgery study eye Intraocular surgery study eye within three month screen Periocular ocular infection study eye Severe myopia ( spherical equivalent 8 diopter great ) study eye History vascular pigment epithelial detachment submacular hemorrhage fellow eye . General Use investigational agent participation clinical trial investigational agent investigational therapy potential affect disease process ( neovascular AMD ) study eye within sixty ( 60 ) day Baseline ( Day 1 ) , participation clinical trial investigational agent investigational therapy within thirty ( 30 ) day Baseline ( Day 1 ) . Participation clinical trial oral supplement vitamins mineral prevention neovascular AMD ( e.g . AREDS2 ) allow , study involve administration investigational agent and/or investigational therapy Undiagnosed acute illness first observe screen screen baseline , severe concurrent medical condition , investigator 's judgment , represent safety concern . Allergy prior significant adverse reaction fluorescein Any major surgical procedure within one month trial entry Blood pressure &gt; 160/90 mmHg .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>